Holen Sie sich die Stockscreener-App
399.98
0.20%
-1.02
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$401.00
Offen:
$400.09
24-Stunden-Volumen:
165.86K
Relative Volume:
0.10
Marktkapitalisierung:
$102.57B
Einnahmen:
$11.39B
Nettoeinkommen (Verlust:
$3.64B
KGV:
28.59
EPS:
13.99
Netto-Cashflow:
$3.50B
1W Leistung:
+2.86%
1M Leistung:
-13.40%
6M Leistung:
-17.20%
1J Leistung:
-15.87%
1-Tages-Spanne:
$399.07
$402.39
1-Wochen-Bereich:
$388.00
$402.39
52-Wochen-Spanne:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
400.04 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.56 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.79 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
714.25 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.68 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Why Vertex Pharmaceuticals (VRTX) Is on Loomis Sayles Growth Fund’s Detractors List - AInvest
Is Vertex Pharmaceuticals Incorporated meeting your algorithmic filter criteriaMarket Volume Summary & Entry and Exit Point Strategies - Newser
Vertex teams with Enlaza to expand gene therapy options - The Pharma Letter
Sentiment analysis tools applied to Vertex Pharmaceuticals Incorporated2025 Market WrapUp & Safe Entry Zone Tips - Newser
Does Vertex Pharmaceuticals Incorporated meet Warren Buffett’s criteriaQuarterly Trade Review & Growth-Oriented Investment Plans - khodrobank.com
What does recent volatility data suggest for Vertex Pharmaceuticals IncorporatedJuly 2025 Catalysts & Smart Swing Trading Alerts - Newser
Stock Analysis | Vertex Pharmaceuticals OutlookMixed Technicals but Strong Fundamentals - AInvest
Vertex Stock Surges 2.55% on 44% Volume Spike to $740M Ranking 135th as $2B Collaboration with Enlaza Drives Strategic Expansion - AInvest
Vertex locks on to $2B covalent biologics deal with Enlaza - FirstWord Pharma
Enlaza takes the helm in a $2B+ Vertex deal - BioWorld MedTech
Relative strength of Vertex Pharmaceuticals Incorporated in sector analysis2025 Investor Takeaways & Weekly Consistent Profit Watchlists - Newser
Does Vertex Pharmaceuticals Incorporated outperform in volatile markets2025 Fundamental Recap & Safe Entry Zone Tips - khodrobank.com
Vertex Pharmaceuticals Partners with Enlaza Therapeutics in $45 Million Deal to Develop Autoimmune and Gene-Editing Therapies - geneonline.com
Vertex enlists Enlaza for gene therapy conditioning and autoimmune disease pact - Endpoints News
Vertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact - BioSpace
Vertex Pharma, Enlaza sign R&D pact worth up to $2B plus equity - Seeking Alpha
Vertex forges $2B-plus alliance with Enlaza to create new autoimmune drugs, improve conditioning methods - Fierce Biotech
Vertex Pharmaceuticals Incorporated (VRTX) Slid on Softer Revenue and Earnings - Yahoo Finance
Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases | VR - GuruFocus
Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases - Business Wire
Is Vertex Pharmaceuticals Incorporated still worth holding after the dipQuarterly Profit Review & Real-Time Buy Signal Alerts - Newser
Aug EndMonth: Does Vertex Pharmaceuticals Incorporated have declining or rising EPS2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - khodrobank.com
Should you wait for a breakout in Vertex Pharmaceuticals IncorporatedQuarterly Performance Summary & Weekly High Return Stock Opportunities - Newser
Is Vertex Pharmaceuticals Incorporated part of any major indexPortfolio Growth Summary & Community Verified Watchlist Alerts - خودرو بانک
Is Vertex Pharmaceuticals Incorporated currently under institutional pressureJuly 2025 Sector Moves & Free AI Powered Buy and Sell Recommendations - khodrobank.com
Vertex Pharmaceuticals’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Vertex Pharmaceuticals Incorporated stock retracement – recovery analysis2025 Big Picture & Safe Capital Growth Trade Ideas - Newser
Using Bollinger Bands to evaluate Vertex Pharmaceuticals IncorporatedWeekly Stock Analysis & Free Fast Gain Swing Trade Alerts - Newser
Risk adjusted return profile for Vertex Pharmaceuticals Incorporated analyzedTrend Reversal & Free Reliable Trade Execution Plans - Newser
Vertex price shows more negative signsForecast today01-09-2025 - Economies.com
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - uk.finance.yahoo.com
Vertex Pharmaceuticals Incorporated stock trendline breakdownAnalyst Downgrade & Entry Point Confirmation Signals - Newser
Tools to monitor Vertex Pharmaceuticals Incorporated recovery probabilityTrade Analysis Summary & Capital Efficiency Focused Strategies - Newser
Price momentum metrics for Vertex Pharmaceuticals Incorporated explainedWeekly Trade Report & AI Forecasted Entry and Exit Points - Newser
Vertex Pharmaceuticals Incorporated Builds Base for Possible Rebound getLinesFromResByArray error: size == 0 - thegnnews.com
Visualizing Vertex Pharmaceuticals Incorporated stock with heatmapsJuly 2025 Sentiment & Free Reliable Trade Execution Plans - Newser
Will earnings trigger a reversal in Vertex Pharmaceuticals IncorporatedPortfolio Performance Summary & Technical Confirmation Trade Alerts - Newser
Is Vertex Pharmaceuticals Incorporated stock reversal real or fake2025 Risk Factors & Safe Capital Growth Trade Ideas - Newser
What high frequency data says about Vertex Pharmaceuticals IncorporatedRate Cut & Daily Risk Controlled Trade Plans - Newser
When is the best time to exit Vertex Pharmaceuticals IncorporatedTrade Exit Summary & Technical Confirmation Trade Alerts - Newser
How to build a custom watchlist for Vertex Pharmaceuticals IncorporatedBear Alert & Real-Time Stock Movement Alerts - Newser
Can Vertex Pharmaceuticals Incorporated recover in the next quarterWeekly Trading Summary & Verified Momentum Watchlists - Newser
Order flow analysis tools used on Vertex Pharmaceuticals Incorporated2025 Technical Overview & Daily Stock Trend Watchlist - Newser
Will breakout in Vertex Pharmaceuticals Incorporated lead to full recoveryEarnings Summary Report & Safe Capital Growth Stock Tips - Newser
Volatility clustering patterns for Vertex Pharmaceuticals IncorporatedDividend Hike & High Accuracy Investment Signals - Newser
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):